Decheng Capital’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$145M Hold
25,954,439
– – 21.22% 2
2026
Q2
$147M Hold
25,954,439
– – 20.15% 2
2026
Q1
$111M Hold
25,954,439
– – 16.84% 2
2025
Q4
$233M Hold
25,954,439
– – 31.28% 2
2025
Q3
$96M Hold
25,954,439
– – 16.75% 2
2025
Q2
$50.6M Hold
25,954,439
– – 12.78% 3
2025
Q1
$45.7M Hold
25,954,439
– – 12.81% 2
2024
Q4
$69M Hold
25,954,439
– – 14.81% 2
2024
Q3
$59.4M Buy
25,954,439
+19,004,200
+273% +$58M 14.08% 2
2024
Q2
$20.3M Buy
+6,950,239
New +$21.2M 6.22% 2

Other funds holding NUVB

Decheng Capital's NUVB Position: Q3 2026 in Review

Decheng Capital held its Nuvation Bio (NUVB) position steady in Q3 2026 at 25,954,439 shares worth $145M. The position accounts for 21.22% of the portfolio, ranked #2.

Decheng Capital first reported a position in NUVB in Q2 2024 and has held it in 10 quarters since. The position peaked at $233M in Q4 2025. 259 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • Decheng Capital held 25,954,439 shares of Nuvation Bio worth $145M as of Q3 2026.
  • Decheng Capital left its Nuvation Bio share count unchanged in Q3 2026.
  • Nuvation Bio made up 21.22% of Decheng Capital's portfolio in Q3 2026, its #2 holding.
  • Decheng Capital first reported a position in Nuvation Bio in Q2 2024 and has held it in 10 quarters since.
  • Decheng Capital's Nuvation Bio position peaked at $233M in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on Decheng Capital's 13F filing for Q3 2026, filed 13 Nov 2026.